

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EVEREST MEDICINES

云 頂 新 耀

Everest Medicines Limited

雲頂新耀有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1952)

**VOLUNTARY ANNOUNCEMENT
COMMERCIALIZATION COLLABORATION RELATING TO
HAINAN HERUI'S BUDESONIDE ENTERIC CAPSULES**

This announcement is made by Everest Medicines Limited (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company entered into commercialization collaboration (the “**Collaboration**”) with Hainan Herui Pharmaceutical Co., Ltd. (“**Hainan Herui**”) relating to Hainan Herui’s budesonide enteric capsules, which were approved by the National Medical Products Administration (NMPA) in December 2025.

Pursuant to the Collaboration, Hainan Herui’s budesonide enteric capsules will be permitted to be launched in the Chinese Mainland market, with the Company’s responsible for its commercialization. The Company will provide rigorous technical guidance and quality audits over Hainan Herui’s manufacturing and supply processes. The Collaboration is expected to enhance patient access to the combined franchise of NEFECON[®] and Hainan Herui’s budesonide enteric capsules. The Collaboration is subject to the satisfaction of customary closing conditions.

ABOUT NEFECON[®]

NEFECON[®] is an oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. NEFECON[®] was designed as a 4 mg delayed release capsule and is enteric coated so that it would remain intact until it reaches the ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum, including the Peyer’s patches, which are responsible for the production of galactose-deficient IgA1 antibodies (Gd-IgA1) causing IgA nephropathy. In June 2019, the Company entered into an exclusive, royalty-bearing license agreement with Calliditas Therapeutics, which gives the

Company exclusive rights to develop and commercialize NEFECON[®] in mainland China, Hong Kong, Macau, Taiwan, China and Singapore. The agreement was extended in March 2022 to include South Korea as part of the Company territories.

By order of the Board
Everest Medicines Limited
Yifang Wu
Chairman and Executive Director

Hong Kong, 24 June 2026

As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. William Ki Chul Cho and Mr. Xin Sun as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.